{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:48Z","timestamp":1790790828494,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ferring Pharmaceuticals A\/S, Kastrup, Denmark"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>How do ovarian responses using conventional dosing for follitropin delta 15\u2009\u00b5g\/day compare with follitropin alfa 225\u2009IU\/day in women undergoing ovarian stimulation?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>The ADAPT-1 trial demonstrates similar ovarian responses with follitropin delta 15\u2009\u00b5g\/day and follitropin alfa 225\u2009IU\/day starting doses in a conventional dosing regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Follitropin delta, a recombinant FSH (rFSH), is currently approved for ovarian stimulation using an individualized fixed daily dose based on serum anti-M\u00fcllerian hormone (AMH) and bodyweight (maximum 12\u2009\u00b5g\/day for first cycle and 24\u2009\u00b5g\/day in subsequent cycles). Other rFSHs, such as follitropin alfa, conventionally apply a starting dose of 150\u2013225\u2009IU, fixed for the initial days of stimulation, after which dose adjustments can be made (maximum 450\u2009IU\/day). Ovarian stimulation with follitropin delta 10\u2009\u00b5g\/day provides a similar ovarian response to follitropin alfa 150\u2009IU\/day for serum concentration and number of follicles \u226512\u2009mm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>ADAPT-1 was a randomized, accessor-blinded, multicentre trial comparing efficacy and safety of a starting dose of follitropin delta 15\u2009\u00b5g\/day with follitropin alfa 225\u2009IU\/day in conventional dosing regimens. The primary endpoint was the number of oocytes retrieved; mean difference between treatment groups was estimated using a negative binomial regression model (treatment and serum AMH level as factors). During the follow-up period, clinical pregnancies resulting from the first fresh\/frozen transfers within 3\u2009months of the start of stimulation, and ovarian hyperstimulation syndrome (OHSS) rates were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Participants, 18\u201340\u2009years, undergoing IVF\/ICSI could enrol at specialist reproductive clinics in Austria, France, Italy, Spain, and the United Kingdom for ovarian stimulation if they had no contraindications for treatment with a starting gonadotropin dose of 225\u2009IU\/day. Patients could enrol if they reported infertility for at least 1\u2009year if \u226437\u2009years and at least 6\u2009months for those &amp;gt;37\u2009years, and regular menstrual cycles (21\u201335\u2009days). All cycles used a GnRH antagonist protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Between 1 August 2022 and 16 April 2024, 300 of 337 screened patients were randomized to, and received, follitropin delta (n\u2009=\u2009200) or follitropin alfa (n\u2009=\u2009100). The two treatment groups were comparable in terms of demographics, baseline characteristics, and duration of infertility. The mean duration of treatment was \u223c9\u2009days in both groups. The mean total dose of follitropin delta was 143.7\u2009\u00b1\u200933.6\u2009\u00b5g and 154.3\u2009\u00b1\u200923.1\u2009\u00b5g (2105\u2009\u00b1\u2009315\u2009IU) for follitropin alfa. Three-quarters (226\/300) used an human Chorionic Gonadotropin trigger for final follicular maturation. A mean of 9.9 oocytes was retrieved for both groups (estimated difference: 0.0 oocytes; 95% CI \u22121.3, 1.2). The category of 8\u201314 oocytes retrieved was the most common ovarian response (follitropin delta: 45.5%; follitropin alfa: 50.0%). Clinical pregnancy rates were comparable (31.6% and 31.0%; estimated difference 0.6 (95% CI \u221210.6, 11.8)). Early OHSS (\u22649\u2009days after triggering) occurred in 2.5% and 3.0%, and all cases were Grade 3 (moderate) or lower. No participant had the stimulation cycle cancelled due to excessive ovarian response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Only pregnancies from the first fresh or cryopreserved transfer within 3\u2009months of oocyte retrieval were recorded. Cumulative pregnancy rates after the first transfer were not followed up. All analyses are of descriptive nature and no formal hypothesis testing or multiplicity adjustment was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>Treatment groups had similar ovarian responses, supporting equivalence for starting doses follitropin delta 15\u2009\u00b5g and follitropin alfa 225\u2009IU, with low rates of early OHSS. Ovarian stimulation cycles with follitropin delta in \u00b5g can be planned and adjusted, leveraging the established IU dose equivalence to follitropin alfa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>This trial was funded by Ferring Pharmaceuticals A\/S, Kastrup, Denmark. Medical writing support for manuscript development was provided by Celia J. Parkyn, PhD, and was funded by Ferring Pharmaceuticals A\/S, Kastrup, Denmark. P.Z. and R.A. have none. A.B. has received grants from Gedeon Richter, IBSA, GP Pharm &amp; Seid, Miguel Hernandez University, Centre for Technological Development and Innovation, Valencian Innovation Agency, Regional Secretary for Industry, Trade and Consumption, and the Government Ministry of Industry and Tourism; payments from University Complutense of Madrid, Ferring Pharmaceuticals, Fentypharm, Miguel Hernandez University, Gedeon Richter, &amp; Vall d\u2019Hebron Hospital; travel support from Ferring Pharmaceuticals, Fentypharm, Gedeon Richter, International ESHRE Congress Organising Committee, Spanish Society of Gynaecology and Obstetrics, CROG Congress Organising Committee, &amp; Vall d\u2019Hebron Hospital; has a patent pending for Sperm plate (U202431456); and is Chair of the Organising Committee of the Infertility and Sterility Section of the Spanish Society of Gynaecologist (non-paid role) and equipment from Obstetrics; &amp; equipment from Cook Medical. J.S. has received consulting fees from Ferring Pharmaceuticals. E.P. has received grants from Merck, Ferring, Theramex, Gedeon Richter, IBSA, and Organon; payments from Merck, Ferring, IBSA, and Organon; travel support from Merck, IBSA, Organon, Theramex, and Ferring; and participated in a Safety Monitoring Board or Advisory Board for Merck. M.G.S. has received patient medication from Ferring; payments from Ferring, Merck for educational events; and travel support from Ferring, Merck, Theramex, and IBSA. R.L. and S.M. are employees of Ferring Pharmaceuticals. I.E.J. was an employee of Ferring Pharmaceuticals at the time of the trial conduct.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>clinicaltrials.gov NCT05263388; Eudract 2021-001785-38<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION DATE<\/jats:title>\n                    <jats:p>16 November 2021 (clinicaltrials.gov); 5 August 2021 (Eudract)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATE OF FIRST PATIENT\u2019S ENROLMENT<\/jats:title>\n                    <jats:p>1 August 2022<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deaf119","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:51:56Z","timestamp":1749714716000},"page":"1660-1670","source":"Crossref","is-referenced-by-count":6,"title":["Ovarian stimulation with follitropin delta for\n                    <i>in vitro<\/i>\n                    fertilization: a multicentre, randomized, assessor-blind comparison with follitropin alfa using conventional dosing regimens (ADAPT-1 trial)"],"prefix":"10.1093","volume":"40","author":[{"given":"Andrea","family":"Bernabeu","sequence":"first","affiliation":[{"name":"Instituto Bernabeu Alicante, Albufereta , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Zajc","sequence":"additional","affiliation":[{"name":"Babywunsch Klinik Dr Zajc , Wals-Siezenheim,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garc\u00eda S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Quir\u00f3nsalud M\u00e1laga Hospital , M\u00e1laga,","place":["Spain"]},{"name":"IVI M\u00e1laga , M\u00e1laga,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Reproductive Medicine, University Hospitals Coventry and Warwickshire NHS Trust , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Papaleo","sequence":"additional","affiliation":[{"name":"Reproductive Sciences Unit, San Raffaele Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Jirecek","sequence":"additional","affiliation":[{"name":"Kinderwunschzentrum Doebling , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"M\u00f8gelmose","sequence":"additional","affiliation":[{"name":"Global Biometrics, Ferring Pharmaceuticals , Kastrup,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Engberg","family":"Jepsen","sequence":"additional","affiliation":[{"name":"Global Research and Medical, Ferring Pharmaceuticals , Kastrup,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1578-9793","authenticated-orcid":false,"given":"Rita","family":"Lobo","sequence":"additional","affiliation":[{"name":"Global Research and Medical, Ferring Pharmaceuticals , Kastrup,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2025111502263649400_deaf119-B1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.rbmo.2020.07.006","article-title":"Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU\/day follitropin alfa","volume":"41","author":"Arce","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2025111502263649400_deaf119-B2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antiM\u00fcllerian hormone-stratified, dose\u2013response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"2025111502263649400_deaf119-B3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejogrb.2019.07.032","article-title":"A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha","volume":"241","author":"Barakhoeva","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025111502263649400_deaf119-B4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12958-021-00744-x","article-title":"Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007\u20132017)","volume":"19","author":"Fatemi","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2025111502263649400_deaf119-B5","volume-title":"Towards Reproductive Certainty. The Plenary Proceedings of the 11th World Congress on in Vitro Fertilisation and Human Reproductive Genetics","author":"Gardner","year":"1999"},{"key":"2025111502263649400_deaf119-B6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"2025111502263649400_deaf119-B7","doi-asserted-by":"crossref","first-page":"e0149615","DOI":"10.1371\/journal.pone.0149615","article-title":"Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol","volume":"11","author":"Griesinger","year":"2016","journal-title":"PLoS One"},{"key":"2025111502263649400_deaf119-B8","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.18632\/aging.102919","article-title":"Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer","volume":"12","author":"Hu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2025111502263649400_deaf119-B9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2025111502263649400_deaf119-B10","doi-asserted-by":"crossref","first-page":"104451","DOI":"10.1016\/j.rbmo.2024.104451","article-title":"Oocyte yield and live birth rate after follitropin delta dosing and fresh embryo transfer: an individual patient data meta-analysis","volume":"50","author":"Lobo","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"2025111502263649400_deaf119-B11","doi-asserted-by":"crossref","DOI":"10.1093\/humrep\/deae092","article-title":"BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle","author":"Lobo","year":"2024","journal-title":"Hum Reprod"},{"key":"2025111502263649400_deaf119-B12","doi-asserted-by":"crossref","first-page":"742089","DOI":"10.3389\/fendo.2021.742089","article-title":"Recombinant human follicle-stimulating hormone alfa dose adjustment in us clinical practice: an observational, retrospective analysis of a real-world electronic medical records database","volume":"12","author":"Mahony","year":"2021","journal-title":"Front Endocrinol"},{"key":"2025111502263649400_deaf119-B13","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Nyboe","year":"2006","journal-title":"Hum Reprod"},{"key":"2025111502263649400_deaf119-B14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"2025111502263649400_deaf119-B15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/jcph.328","article-title":"Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line","volume":"54","author":"Olsson","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2025111502263649400_deaf119-B16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","article-title":"Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"85","author":"Papanikolaou","year":"2006","journal-title":"Fertil Steril"},{"key":"2025111502263649400_deaf119-B17","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum Reprod"},{"key":"2025111502263649400_deaf119-B18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.rbmo.2015.01.005","article-title":"A multi-centre phase 3 study comparing efficacy and safety of Bemfola((R)) versus Gonal-f((R)) in women undergoing ovarian stimulation for IVF","volume":"30","author":"Rettenbacher","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"2025111502263649400_deaf119-B19","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1001\/jama.2015.17296","article-title":"Live-birth rate associated with repeat in vitro fertilization treatment cycles","volume":"314","author":"Smith","year":"2015","journal-title":"Jama"},{"key":"2025111502263649400_deaf119-B20","doi-asserted-by":"crossref","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI(dagger)","volume":"2020","author":"The ESHRE Guideline Group on Ovarian Stimulation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2025111502263649400_deaf119-B21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.rbmo.2021.08.024","article-title":"Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Mullerian hormone and body weight","volume":"43","author":"Vi\u0161nov\u00e1","year":"2021","journal-title":"Reprod Biomed Online"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/9\/1660\/63714154\/deaf119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/9\/1660\/63714154\/deaf119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T07:26:43Z","timestamp":1763191603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/40\/9\/1660\/8195902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaf119","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,9]]}}}